Tags : Rituximab

Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III

Shots: The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing treatment The P-II study met its 1EP of prolonged PFS, safety is consistent with previously published data on the individual components […]Read More

Innovent and Lilly’s Halpryza (biosimilar, rituximab) Receive NMPA’s Approval in

Shots: NMPA has approved Halpryza for patients with DLBCL, FL, and CLL in China. The biosimilar is the fourth mAb approved in China following the approval of Tyvyt (biosimilar, sintilimab), Byvasda (biosimilar, bevacizumab) and Sulinno (biosimilar, adalimumab) The clinical efficacy and safety of rituximab in CD20 +ve NHL have been confirmed in multiple large-scale clinical […]Read More

Cadila to Launch its Ritucad (rituximab, biosimilar) in India

Shots: Cadila to strengthen its biosimilar portfolio and oncology footprints in India with the launch of Ritucad and has cleared USFDA inspection in Feb’20 Additionally, the company has launched its Bevaro (bevasizumab, biosimilar) a mAb targeted for multiple cancer indications like Ovarian Cancer, Glioblastoma Multiforme (a type of Brain cancer), Colorectal Cancer, Breast Cancer, Lung […]Read More

Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in

Shots: Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma In the 13 patients who underwent disease assessment following the R2A regimen, ORR (69%) and CR (31%), […]Read More

Pfizer’s Ruxience (biosimilar, rituximab) Receives EC’s Approval for Cancer Indications

Shots: The EC’s approval is based on the REFLECTIONS B3281006 study assessing efficacy, safety and immunogenicity, PK/PD of Ruxience that demonstrated the bio-similarity of Ruxience of its reference product, MabThera (rituximab) The approval follows the CHMP’s positive opinion received in Jan’2020. The therapy is made available to the adult patients with NHL, CLL, GPA and […]Read More

iBio Supports AzarGen’s Development of a Biosimilar to Rituximab

Shots::sttohthshots: iBio enters a second statement of work under its MJDA with AzarGen, signed in 2018. The MJDA intends initial contract development and manufacturing of AzarGen’s biosimilars at iBio’s Bryan, Texas facility iBio plans to transfer its FastPharming Manufacturing System to AzarGen in South Africa to produce medicines in the African continent. By leveraging iBio’s […]Read More